Tumor Board Articles

What is the optimal treatment course for hepatocellular carcinoma patients that are potential candidates for liver transplant? This article reviews bridging and downstaging techniques, surgical planning after locoregional therapy, and the emerging risks of immunotherapy in transplant patients.

Treatment of hepatocellular carcinoma often involves multidisciplinary evaluation to determine candidacy for surgical resection or transplant. This article outlines surgical indications and techniques used to treat or bridge patients to transplant.

Interventional radiologist Dr. Richard Finn and medical oncologist Dr. Julius Chapiro cover recent HCC clinical trials, including EMERALD-1, LEAP-012, REFLECT, IMbrave150, and CheckMate-9DW.

As HCC treatment options continue to evolve, clinicians must weigh an expanding arsenal of modalities like locoregional therapy TACE and systemic immunotherapy. Drs. Julius Chapiro and Richard Finn explain the decision process behind selecting and timing these treatment modalities.

Immunotherapy for HCC has transformed treatment for advanced liver cancer, with landmark trials like IMbrave150, Himalaya, and CheckMate-9DW redefining first-line options. Learn about these trials and their implications for survival benefits, combination strategies, and the role of tumor etiology.

Portal Vein Thrombosis (PVT) can complicate liver transplant eligibility and surgical planning. Learn how transplant teams assess and manage PVT in liver transplant candidates, including surgical, interventional, and anticoagulative strategies.

Post-transplant HCC recurrence poses a considerable challenge and requires comprehensive surveillance and interventional management. Learn about key approaches to managing HCC recurrence and other post-transplant complications such as biliary stricture and organ rejection.